A size exclusion-reversed phase two dimensional-liquid chromatography methodology for stability and small molecule related species in antibody drug conjugates

Journal of Chromatography A

Volumn 1393, Issue , 2015, Pages 81-88

  Li, Yi ^a   Gu, Christine ^a   Gruenhagen, Jason ^a   Zhang, Kelly ^a   Yehl, Peter ^a   Chetwyn, Nik P ^a   Medley, Colin D ^a  

^a GENENTECH INC   (United States)

Author keywords

2D LC; Antibody drug conjugates

Indexed keywords

ANTIBODIES; DEGRADATION; DIMERS; DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; MOLECULES;

2D-LC; ADC CHARACTERIZATION; ANTIBODY-DRUG CONJUGATES; DEGRADATION PATHWAYS; DEGRADATION PRODUCTS; FORMULATION DEVELOPMENT; SMALL-MOLECULE DRUGS; TWO-DIMENSIONAL LIQUID CHROMATOGRAPHY;

SIZE EXCLUSION CHROMATOGRAPHY;

ANTIBODY; ANTIBODY DRUG CONJUGATE; DIMER; MONOMER; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

ARTICLE; DEGRADATION; GEL PERMEATION CHROMATOGRAPHY; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; PH; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; SEPARATION TECHNIQUE; SIZE EXCLUSION REVERSED PHASE TWO DIMENSIONAL LIQUID CHROMATOGRAPHY; TEMPERATURE; CHEMISTRY; GEL CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROCEDURES; REVERSED PHASE LIQUID CHROMATOGRAPHY;

ANTIBODIES; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; IMMUNOCONJUGATES; MASS SPECTROMETRY;

EID: 84926515510     PISSN: 00219673     EISSN: 18733778     Source Type: Journal    
DOI: 10.1016/j.chroma.2015.03.027     Document Type: Article

References (33)

1. Larson R.A., Sievers E.L., Stadtmauer E.A., Löwenberg B.E.H., Estey H., Dombret, Theobald M., Voliotis D., Bennett J.M., Richie M., Leopold L.H., Berger M.S., Sherman M.L., Loken M.R., Dongen J.J.M., Bernstein I.D., Appelbaum F.R. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104:1442-1452.
2. Alley S.C., Okeley N.M., Senter P.D. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 2010, 14:529-537.
3. LoRusso P.M., Weiss D., Guardino E., Girish S., Sliwkowski M.X. Trastuzumab emtansine: a unique antibody-drug conjugate in development of human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 2011, 17:6437-6447.
4. Chari R.V.J. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 2008, 41:98-107.
5. Hamann P.R., Hinman L.M., Hollander C.F., Beyer D., Holcomb R., Hallet W., Tsou H.R., Upeslacis J., Shocat D., Mountain A., Flowers D.A., Bernstein I. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconj. Chem. 2002, 13:47-58.
6. Doronina S.O., Toki B.E., Torgov M.Y., Mendelsohn B.A., Cerveny C.G., Chace D.F., DeBlanc R.L., Gearing R.P., Bovee T.D., Siegall C.B., Francisco J.A., Wahl A.F., Meyer D.L., Senter P.D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21:778-784.
7. Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 2005, 23:1137-1146.
8. Chari R.V. Targeted delivery of chemotherapeutics tumor-activated prodrug therapy. Adv. Drug Deliv. Rev. 1998, 31:89-104.
9. Lambert J.M. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol. 2005, 5:543-549.
10. Payne G. Progress in immunoconjugate cancer therapeutics. Cancer Cell 2003, 3:207-212.
11. Wakankar A., Chen Y., Gokarn Y., Jacobson F.S. Analytical methods for physiochemical characterization of antibody drug conjugates. mAbs 2011, 3(2):161-172.
12. Alley S.C., Anderson K.E. Analytical and bioanalytical technologies for characterizing antibody-drug conjugates. Curr. Opin. Chem. Biol. 2013, 17:406-411.
13. Sanderson R.J., Hering M.A., James S.F., Sun M.M., Doronina S.O., Siadak A.W., Senter P.D., Wahl A.F. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 2005, 11:843-852.
14. Kovtun Y.V., Audette C.A., Ye Y., Xie H., Ruberti M.F., Phinney S.J., Leece B.A., Chittenden T., Blattler W.A., Goldmacher V.S. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006, 66:3214-3221.
15. Dong M. Modern HPLC for Practicing Scientists 2006, 135-156. John Wiley & Sons.
16. Li Y., Medley C., Zhang K., Wigman L., Chetwyn N. Limiting degradation of reactive antibody drug conjugate intermediates in HPLC method development. J. Pharm. Biomed. Anal. 2014, 92:114-118.
17. Hudecz F., Garnett M.C., Khan T., Baldwin R.W. The influence of synthetic conditions on the stability of methotrexate-monoclonal antibody conjugates determined by reserved phase high performance liquid chromatography. Biomed. Chromatogr. 1992, 6:128-132.
18. Hurwitz E., Levy R., Maron R., Wilchek M., Arnon R., Sela M. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res. 1975, 35:1175-1181.
19. Chari R.V., Jackel K.A., Bourret L.A., Derr S.M., Tadayoni B.M., Mattocks K.M. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 1995, 55:4079-4084.
20. Greenfield R.S., Kaneko T., Daues A., Edson M.A., Fitzgerald K.A., Olech L.J., Grattan J.A., Spitalny G.L., Braslawsky G.R. Evaluation in vitro of Adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res. 1990, 50:6600-6607.
21. Evans C.R., Jorgenson J.W., Cohen S.A., Schure M.R. Multidimensional Liquid Chromatography 2008, 177. John Wiley & Sons.
22. Stoll D.R., Wang X.L., Carr P.W. Comparison of the practical resolving power of one- and two-dimensional high-performance liquid chromatography analysis of metabolomic samples. Anal. Chem. 2008, 80:268-278.
23. Pascoe R., Foley J.P., Gusev A.I. Reduction in matrix-related signal suppression effects in electrospray ionization mass spectrometry using on-line two-dimensional liquid chromatography. Anal. Chem. 2001, 73:6014-6023.
24. Matejicek D. Multi heart-cutting two-dimensional liquid chromatography' Äìatmospheric pressure photoionization-tandem mass spectrometry method for the determination of endocrine disrupting compounds in water. J. Chromatogr. A 2012, 1231:52-58.
25. Groskreutz S.R., Swenson M.M., Secor L.B., Stoll D.R. Selective comprehensive multi-dimensional separation for resolution enhancement in high performance liquid chromatography. J. Chromatogr. A 2012, 1228:31-40.
26. Opiteck G.J., Jorgenson J.W., Anderegg R.J. Two-dimensional SEC/RPLC coupled to mass spectrometry for the analysis of peptides. Anal. Chem. 1997, 69:2283-2291.
27. Stoll D.R., Li X., Wang X., Carra P.W., Porterv S.E., Rutan S.C. Fast, comprehensive two-dimensional liquid. J. Chromatogr. A 2007, 1168:3-43.
28. He Y., Friese O.V., Schlittler M.R., Wang Q., Yang X., Bass L.A., Jones M.T. On-line coupling of size exclusion chromatography with mixed-mode liquid chromatography for comprehensive profiling of biopharmaceutical drug product. J. Chromatogr. A 2012, 1262:122-129.
29. Zhang K., Li Y., Tsang M., Chetwyn N.P. Analysis of pharmaceutical impurities using multi-heartcutting 2D LC coupled with UV-charged aerosol MS detection. J. Sep. Sci. 2013, 36:2986-2992.
30. Li Y., Hewitt D., Yvonne K., Li J., Zhang T., Zhang K. Characterization and stability study of polysorbate 20 in therapeutic monoclonal antibody formulation by multidimensional ultrahigh performance liquid chromatography-charged aerosol detection-mass spectrometry. Anal. Chem. 2014, 86:5150-5157.
31. Rosenberg A.S., Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 1: considering consequences of the immune response to a protein. Biopharm. Int. 2004, 19:22-26.
32. Rosenberg A.S., Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 2: considering host-specific and product-specific factors imacting immunogenicity. Biopharm. Int. 2004, 19:34-42.
33. Zhang T.Y., Quan C., Dong M.W. HPLC for characterization and quality control of therapeutic monoclonal antibodies. LCGC North Am. 2014, 32:796-808.